Kewaunee Scientific (KEQU) Q3 2026 earnings review
Growth Stalls as Backlog Bleeds and Margins Compress
Kewaunee delivered a sobering Q3. While management touted YoY growth, the 3.3% revenue increase was entirely driven by the International segment clearing delayed projects. In the Domestic segment, the base effect of the Nu Aire acquisition has normalized, revealing a 2.0% contraction in sales. More alarmingly, the order backlog has been decelerating for four consecutive quarters, dropping 17% YoY. Profitability compressed significantly, with Adjusted EBITDA dropping 30% YoY as the company absorbed lower factory volumes and higher corporate investments.
🐂 Bull Case
The International segment is accelerating, with sales jumping 21.4% to $18.4M and EBITDA surging 158%. India market billings are finally materializing after previous construction site delays.
The company is aggressively deleveraging. Debt-to-equity ratio improved to 0.68-to-1 from 0.99-to-1 in April 2025, and long-term debt (net of sale-leaseback) was cut by more than half to $16.3M.
🐻 Bear Case
Order backlog has steadily declined from $221.6M a year ago to $183.2M today. Without replenishment, future revenue growth is mathematically constrained.
With the Nu Aire acquisition fully lapped, Domestic sales reversed into negative territory (-2.0%), exposing underlying softness in the core laboratory construction business.
⚖️ Verdict: 🔴
Bearish. The organic growth engine is stalling. While International execution is commendable, the steady depletion of the order backlog and compressing Domestic margins paint a tough picture for the coming quarters.
Key Themes
Organic Growth Contradicts Management Optimism
Management noted that delivering year-over-year growth underscores the value of their strategy. However, the data contradicts this optimism. The 3.3% consolidated revenue growth masks a concerning reversal in the Domestic segment, which shrank 2.0% to $51M. Because the Nu Aire acquisition closed in Q3 of last year, the massive +50% YoY growth rates seen in Q1 and Q2 have evaporated, revealing organic volume declines.
Order Backlog Evaporation
The order backlog is visibly decelerating, falling 17.3% YoY to $183.2M. This marks the fourth consecutive quarter of sequential backlog decline. Management historically cited customer site delays as the reason for high backlogs, but as those projects are finally billed, new orders are clearly failing to replenish the pipeline at the same rate.
Macro Volatility and Construction Delays
Management explicitly cited significant geopolitical and economic uncertainty exacerbating a general winter slowdown in construction schedules. This macroeconomic headwind is actively decelerating the core laboratory construction portion of the business, creating uneven project delivery timelines.
International Execution Accelerating
The International segment remains a bright spot, accelerating its profitability. Despite a history of site delays in India, the segment successfully converted backlog to revenue this quarter, driving sales up 21.4% and rocketing segment EBITDA from $0.76M to $1.96M.
Nu Aire End-User Products Providing a Floor
The integration of Nu Aire is serving its strategic purpose. Demand for specific end-user containment products, such as biological safety cabinets and CO2 incubators, remains stable. This product diversification is actively offsetting the severe cyclical weakness in the heavier laboratory construction business.
Aggressive Deleveraging
The company's cash generation over the past 9 months has been effectively deployed to clean up the balance sheet. Long-term debt (net of the sale-leaseback transaction) is accelerating downward, moving from $34.1M in April 2025 to $16.3M today. This significantly derisks the company ahead of a potential construction downcycle.
Other KPIs
Decelerating. Adjusted EBITDA margin dropped significantly from 8.5% in 25Q3 to 5.7% in 26Q3. The decline highlights negative operating leverage as lower factory volumes in Domestic manufacturing failed to cover fixed costs.
Stable but heavy burden. Corporate overhead remains elevated at a $2.26M quarterly burn rate (flat YoY). Management defends this as necessary strategic investments in people, financial consolidation systems, and SEC accelerated reporting readiness to support future M&A.
Guidance
Stable. In previous quarters, management guided that FY26 unadjusted EBITDA would exceed FY25's $21.6M. With YTD FY26 EBITDA at $15.9M, the company only needs $5.7M in Q4 to achieve this goal. Given that Q4 historically benefits from stronger seasonality (last year Q4 delivered $9.6M), this guidance remains highly achievable despite the current quarter's margin compression.
Key Questions
Backlog Floor
Order backlog has declined by nearly $40 million over the past year. What is the normalized run-rate for backlog in the current macro environment, and when do you expect the book-to-bill ratio to return to 1.0?
Domestic Manufacturing Leverage
You cited lower manufacturing volumes impacting profitability in the Domestic segment. At what capacity utilization are your plants currently running, and are there plans to right-size fixed costs if construction demand remains soft?
International Sustainability
The International segment saw a massive EBITDA jump this quarter. Is this the new structural run-rate due to clearing delayed high-margin projects in India, or was there a one-time mix benefit that will normalize?